• Explore /
  • Poster
  • / Multicenter phase II clinical trial of everolimus in Japanese patients with unresectable or metastatic renal cell carcinoma (mRCC) after failure of treatment with first-line tyrosine kinase inhibitor (TKI) therapy.

Multicenter phase II clinical trial of everolimus in Japanese patients with unresectable or metastatic renal cell carcinoma (mRCC) after failure of treatment with first-line tyrosine kinase inhibitor (TKI) therapy.

Abstract Poster

Authors

null

Seiichiro Ozono

Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan

Seiichiro Ozono , Masafumi Oyama , Masahiro Nozawa , Kiyohide Fujimoto , Ken Kishida , Noriaki Tokuda , Go Kimura , Kazuo Nishimura , Akio Matsubara , Hideyasu Matsuyama , Takayuki Sugiyama , Tomomi Kamba , Haruki Kume , Naoya Masumori , Mototsugu Oya , Hiro-Omi Kanayama , Seiji Naito , Shiro Hinotsu , Kojiro Shimozuma , Hideyuki Akaza

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Renal Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

UMIN000004742

Citation

J Clin Oncol 32, 2014 (suppl 4; abstr 455)

DOI

10.1200/jco.2014.32.4_suppl.455

Abstract #

455

Poster Bd #

E6

Abstract Disclosures

Similar Posters

First Author: Thomas Cosgriff

First Author: Paul L. de Souza

First Author: Thomas Cosgriff

First Author: Robert Motzer